ImmunityBio, Inc. (IBRX) NASDAQ
7.67
+1.01(+15.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.67
+1.01(+15.17%)
Currency In USD
Address
3530 John Hopkins Court
San Diego, CA 92121
United States of America (the)
Phone
858 633 0300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
671
First IPO Date
July 28, 2015
| Name | Title | Pay | Year Born |
| Richard Gerald Adcock | President, Chief Executive Officer & Director | 1.34M | 1969 |
| David C. Sachs | Chief Financial Officer | 818,647 | 1978 |
| Patrick Soon-Shiong | Executive Chairman of the Board and Global Chief Scientific & Medical Officer | 1.01M | 1953 |
| Barry J. Simon | Chief Corporation Affairs Officer & Director | 0 | 1965 |
| Enrique Diloné | Chief Technology Officer | 0 | 1967 |
| Hans Georg Klingemann | Chief Science Officer of Cellular | 0 | 1950 |
| Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy | 0 | N/A |
| Manju Saxena | Senior Vice President of Product Development & Cell Therapy Program | 0 | N/A |
| Sandeep K. Reddy | Chief Medical Officer | 0 | N/A |
| Emily Arison | Senior Vice President of Human Resources | 0 | N/A |
| Regan J. Lauer | Chief Accounting Officer | 0 | 1970 |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | 0 | N/A |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.